Skip to content
MARKETS / NASDAQ / ANIX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Anixa Biosciences Inc. ANIX

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-10.9M
In brief

What this company does

Our vaccine programs include (i) the development of a vaccine against breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic.

Written from the business description in Anixa Biosciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 January 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.2 · Net income -12.6
4M8M-5M-10M201020122014201620182020202220242025
Compound annual growth
−25.7%
−3.4%
−24.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −3.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2024 · Operating -6586.2% · Net -6046.7%
-2000%-4000%-6000%201020122014201620182020202220242025
ROE
FY2025 · ROE -62.2%
-1000%-2000%201020122014201620182020202220242025

Each USD of equity lost 62 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2020 · FCF -6.2
0.5M1.0M-2.5M-5.0M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2024 · Dividends — · Net buybacks -2.9
-1M-2M2024

Total assetsUSD 16.1M
EquityUSD 15.2M
CashUSD 1.2M
Current ratio8.08×

Equity funds 94% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B·0.00.0·0.0·0.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B·····−0.0−0.0−0.0······−0.0−0.0
Income tax $B··············0.0·
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B·····−0.0−0.0−0.0−0.0−0.00.0−0.0·−0.0−0.0−0.0
EPS, diluted $−0.34−0.39−0.32−0.45−0.45−0.45−0.59−0.79−0.58−0.57−16.00−1.10−0.05−0.02−0.04−0.03
Dividend / sh $················
Payout %················
ROE %−62.2−56.6−36.8−42.2−58.6−143.2−218.3−209.6−112.4−166.1−30.4−2788.6··−261.0−112.6
Shares out B0.030.030.030.030.030.020.020.020.020.010.010.010.210.180.180.15

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 62 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 30 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsOctober 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image